The Board denied a rating in excess of 10 percent for polycythemia vera prior to June 29, 2020.
The deciding factor: There is no evidence that the Veteran required chemotherapy or myelosuppressant therapy at any time prior to June 29, 2020.
- Claimed conditions
- polycythemia vera
- How they argued it
- Direct service connection
- Exposure basis
- None
- Rating assigned
- None in this decision
- Decision date
- July 3, 2025
- Citation
- A25057647
What this means for you
A denial is a starting point, not the end of the road. You can see why this claim fell short — and, if you are still inside the one-year window, the appeal lanes that may remain open to you.
What you can do next
Related decisions
Other Board decisions on a similar condition or argued the same way.
- Granted
The Board granted service connection for polycythemia vera, finding a nexus to in-service herbicide agent exposure.
- Remanded (sent back)
The Board remands the claim for additional development, including verifying the Veteran's claimed exposure to ionizing radiation and providing a new medical opinion.
- Granted
The Board granted an initial 60 percent evaluation for polycythemia vera, as the Veteran was prescribed molecularly targeted therapy to control red blood cell count.
- Remanded (sent back)
The Board remands the claim for service connection for polycythemia vera to obtain additional records from the Veteran's community care provider.
We are not the VA. Veterans’ Rights is an independent resource built for veterans. We are not the U.S. Department of Veterans Affairs, not part of the government, and not endorsed by any government agency.
This is general information, not legal advice. For advice about your own situation, talk to a VA-accredited representative — many help for free.